公开(公告)号：US12122818B2

公开(公告)日：2024-10-22

申请号：US18541682

申请日：2023-12-15

申请人： Novo Nordisk A/S

发明人： Frantisek Hubalek ,  Mathias Norrman ,  Helle Birk Olsen ,  Peter Madsen ,  Thomas Boerglum Kjeldsen ,  Jeppe Sturis

IPC分类号： C07K14/62 ,  A61K47/22 ,  A61P3/10

CPC分类号： C07K14/62 ,  A61K47/22 ,  A61P3/10

摘要： The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.

公开(公告)号：US12060414B2

公开(公告)日：2024-08-13

申请号：US17011321

申请日：2020-09-03

申请人： École Polytechnique Fédérale de Lausanne (EPFL)

发明人： Jeffrey A. Hubbell ,  Stephan Kontos ,  Karen Y. Dane

IPC分类号： C07K16/18 ,  A61K9/107 ,  A61K9/51 ,  A61K38/00 ,  A61K39/00 ,  A61K47/60 ,  A61K47/62 ,  A61K47/64 ,  A61K47/68 ,  A61K47/69 ,  C07K7/08 ,  C07K14/62 ,  C07K14/74 ,  C07K16/28 ,  C12N9/82

CPC分类号： C07K16/18 ,  A61K39/0008 ,  A61K39/001 ,  A61K47/60 ,  A61K47/62 ,  A61K47/64 ,  A61K47/646 ,  A61K47/6811 ,  A61K47/6849 ,  A61K47/6901 ,  C07K7/08 ,  C07K14/62 ,  C07K14/70539 ,  C07K16/2896 ,  C12N9/82 ,  C12Y305/01001 ,  A61K9/1075 ,  A61K9/513 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/6031 ,  A61K2039/6056 ,  A61K2039/627 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/23 ,  C07K2319/33 ,  C07K2319/41 ,  C07K2319/43 ,  C07K2319/74

摘要： Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

公开(公告)号：US20240218041A1

公开(公告)日：2024-07-04

申请号：US18288925

申请日：2022-05-03

申请人： THE TRUSTEES OF INDIANA UNIVERSITY

发明人： Michael A. WEISS ,  Mark A. JAROSINSKI

IPC分类号： C07K14/62 ,  C07K1/107 ,  C12P21/02

CPC分类号： C07K14/622 ,  C07K1/1077 ,  C12P21/02

摘要： A two-chain insulin analogue is provided containing (a) a B chain modified by the addition of a C-terminal diol element in combination with (b) a glucose-binding element attached to the A chain at or near its N terminus, optionally linked to a D-amino acid. A “flipped” set of insulin analogues wherein the A chain is modified by addition of an N-terminal diol element whereas the glucose-binding element is attached at or near the C terminus of the B chain is also provided. Compositions comprising such insulin analogues are used in methods of treating a patient with diabetes mellitus.

公开(公告)号：US20240197846A1

公开(公告)日：2024-06-20

申请号：US18287739

申请日：2022-04-20

申请人： Cue Biopharma, Inc.

发明人： Ronald D. SEIDEL, III ,  John F. ROSS ,  Chee Meng LOW

IPC分类号： A61K39/00 ,  C07K14/47 ,  C07K14/495 ,  C07K14/525 ,  C07K14/55 ,  C07K14/62 ,  C07K14/705 ,  C07K14/74 ,  C12N9/16 ,  C12N9/88

CPC分类号： A61K39/0008 ,  C07K14/47 ,  C07K14/495 ,  C07K14/525 ,  C07K14/55 ,  C07K14/62 ,  C07K14/70532 ,  C07K14/70539 ,  C12N9/16 ,  C12N9/88 ,  C12Y301/03009 ,  C12Y301/03048 ,  C12Y401/01015

摘要： The present disclosure provides antigen presenting polypeptide comprising a TGF-β MOD that is reversibly masked and acts as a TGF-β receptor agonist. The antigen presenting polypeptides comprising one or more chemical conjugation sites for incorporation of, for example, Type 1 Diabetes (T1D) associated epitope containing polypeptides. The antigen-presenting polypeptides and their T1D-associated epitope conjugates are useful for modulating the activity of a T-cell, and accordingly, the present disclosure provides methods of modulating activity of a T-cell in vitro and in vivo as a method of treatment of T1D.

公开(公告)号：US20240190937A1

公开(公告)日：2024-06-13

申请号：US18287630

申请日：2022-04-21

申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services

发明人： Qing-Rong Liu ,  Min Zhu ,  Pingbo Zhang ,  Josephine M. Egan

IPC分类号： C07K14/62 ,  A61K45/06 ,  A61P3/00 ,  A61P25/28 ,  G01N33/68

CPC分类号： C07K14/62 ,  A61K45/06 ,  A61P3/00 ,  A61P25/28 ,  G01N33/6896 ,  G01N2333/62 ,  G01N2800/044 ,  G01N2800/2821

摘要： Methods of treating a subject with diabetes or Alzheimer's disease with a disclosed insulin isoform or Cα polypeptide are provided. Methods of detecting insulin isoforms or Cα polypeptides are also provided.

公开(公告)号：US20240182539A1

公开(公告)日：2024-06-06

申请号：US18581048

申请日：2024-02-19

申请人： Akston Biosciences Corporation

发明人： Thomas M. Lancaster ,  Todd C. Zion

IPC分类号： C07K14/62 ,  C07H21/04 ,  C12N5/16

CPC分类号： C07K14/62 ,  C07H21/04 ,  C07K2319/30 ,  C07K2319/70 ,  C12N5/16

摘要： The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.

公开(公告)号：US11986288B2

公开(公告)日：2024-05-21

申请号：US15912473

申请日：2018-03-05

申请人： MEDTRONIC MINIMED, INC.

发明人： Ashwin K. Rao ,  Rebecca K. Gottlieb ,  Quyen Ong

IPC分类号： A61B5/145 ,  A61B5/1477 ,  A61B5/1486 ,  G01N33/52 ,  G01N33/66 ,  A61B5/00 ,  C07K14/62 ,  C12Q1/00

CPC分类号： A61B5/14532 ,  A61B5/14517 ,  A61B5/1486 ,  G01N33/526 ,  G01N33/66 ,  A61B5/14539 ,  A61B5/14546 ,  A61B5/1477 ,  A61B5/6833 ,  C07K14/62 ,  C12Q1/006

摘要： Described here are patches and methods for measuring glucose in sweat (and tears and the like). In general, the patches comprise an adhesive layer adapted to bond to skin of an individual, a substrate layer disposed over the adhesive layer and comprising a glucose sensing complex including a chromogen that changes color in the presence of certain concentrations of glucose, and a cover. In typical embodiments, the substrate layer has elements formed to direct and accumulate sweat that migrates from the skin of the individual to the glucose sensing complex. Methods of using the invention can comprise cleaning the skin surface, collecting sweat in a patch comprising this microfluidic constellation of elements, and observing concentrations of glucose collected in the sweat, for example either visually, or by using a smartphone or other computer processing device.

公开(公告)号：US20240058442A1

公开(公告)日：2024-02-22

申请号：US18183465

申请日：2023-03-14

申请人： Phaim Pharma Ltd.

发明人： Tihamer ORBAN

IPC分类号： A61K39/395 ,  A61K38/17 ,  A61K45/06 ,  G01N33/50 ,  A61K38/28 ,  A61K39/00 ,  C07K14/47 ,  C07K14/62 ,  C07K14/705

CPC分类号： A61K39/3955 ,  A61K38/1774 ,  A61K45/06 ,  G01N33/5094 ,  A61K38/28 ,  A61K39/0008 ,  C07K14/4713 ,  C07K14/62 ,  C07K14/70521 ,  A61K2039/55566 ,  C07K2319/00 ,  C07K2319/30

摘要： A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith.

公开(公告)号：US20240043493A1

公开(公告)日：2024-02-08

申请号：US18265616

申请日：2021-12-07

申请人： CASE WESTERN RESERVE UNIVERSITY

发明人： Michael A. WEISS ,  Nelson B. PHILLIPS ,  Faramarz ISMAIL-BEIGI

IPC分类号： C07K14/62 ,  A61P3/10

CPC分类号： C07K14/62 ,  A61P3/10

摘要： A single-chain insulin analogue comprises the insulin B-chain polypeptide sequence, the insulin A-chain polypeptide sequence, and a connecting polypeptide sequence of 5-11 amino acids linking the C-terminal amino acid of the B-chain polypeptide to the N-terminal amino acid of the A-chain polypeptide. The analogue comprises an acetylated Lys at a location selected from the group consisting of any of the amino acids in the connecting polypeptide, B0-B3, B28-B29 or A14, relative to wild type insulin, or comprises an acetylated amino acid at the N-terminal amino acid of the single-chain insulin analogue. The single-chain insulin analogue may be acylated with a C6-C21 fatty acid, which may be attached to the e-amino group of a unique Lysine residue or the a-amino group of the N-terminal amino acid of the single-chain insulin analogue. The insulin analogue may be used to lower the blood sugar of a patient in need thereof.

公开(公告)号：US20240010699A1

公开(公告)日：2024-01-11

申请号：US18250471

申请日：2021-11-04

申请人： The Trustees of the University of Pennsylvania

发明人： James M. Wilson ,  Christian Hinderer ,  Makoto Horiuchi

IPC分类号： C07K14/62 ,  C12N15/86 ,  A61P3/10 ,  A61K48/00

CPC分类号： C07K14/62 ,  C12N15/86 ,  A61P3/10 ,  A61K48/005

摘要： Compositions and methods for treating diabetes in a canine are provided. A viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding a canine insulin polypeptide.